Rheumatoid Arthritis

Denosumab Doses Must Be Delivered On Time for Patients With Osteoporosis

August 04, 2020

Article

It is important for clinicians considering prescribing denosumab treatment to counsel patients before its initiation on the importance of not delaying or discontinuing injections.

Tocilizumab Does Not Meet Primary Endpoint in COVID-19 Phase 3 Trial

July 30, 2020

Article

Findings of the trial on tocilizumab fall short.

Upadacitinib Demonstrates Safety and Efficacy for Atopic Dermatitis

July 21, 2020

Article

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

ACR Supports Use of Telemedicine for Rheumatology

July 01, 2020

Article

The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.

Filgotinib Effective for Patients With Rheumatoid Arthritis

June 09, 2020

Article

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Tocilizumab Shows Similar Efficacy to Other Targeted Immune Modulators

June 09, 2020

Article

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

Philip Mease, MD: The Relationship Between Psoriatic Arthritis and IBD

June 07, 2020

Article

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Tofacitinib Reduces Psychiatric Disorder Rates in Rheumatoid Arthritis Patients

June 07, 2020

Article

Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.

Serious Infection More Likely in Older Rheumatoid Arthritis Patients

June 07, 2020

Article

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

Upadacitinib Improves Rheumatoid Arthritis Symptoms Over Abatacept

June 06, 2020

Article

The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.

x